eHIV Review

For clinicians seeking to provide the most effective HIV management, choosing ART for treatment-experienced patients with resistance-associated mutations may present a significant challenge. If a patient has developed resistance to medications from one or more classes of ART, which agents or combinations of agents are most likely to provide adequate treatment? What place should newer antiretroviral drugs have in the treatment armamentarium? 

These are some of the questions Dr. Brian Wood from the Division of Allergy and Infectious Diseases at the University of Washington in Seattle addresses in this issue of eHIV Review.

• Describe the potential role for the NNRTI doravirine for treatment-experienced individuals, including those with a history of specific NNRTI resistance-associated mutations. 
• Discuss potential uses of relatively new FDA-approved antiretroviral agents (including fostemsavir and ibalizumab) as part of combination therapy for heavily treatment-experienced individuals with multiclass drug resistance, plus the possible future role of the investigational capsid inhibitor lenacapavir.